Dyne Therapeutics, Inc. DYN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$451.71M-23.0% | -$446.21M-40.6% | -$423.8M-43.9% | -$412.89M-60.3% | -$367.13M-42.6% | ||
| $2.07M+18.2% | $2.02M+23.7% | $1.95M+23.2% | $1.85M+16.8% | $1.75M+10.5% | ||
| $45.91M+17.8% | $45.85M0.0% | $45.1M+9.7% | $42.77M+14.8% | $38.98M+10.5% | ||
| -$442.24M-38.3% | -$403.21M-37.9% | -$375.71M-54.6% | -$359.56M-64.2% | -$319.73M-45.5% | ||
| $1.16M-63.4% | $1.92M-19.2% | $2.51M+81.6% | $2.37M+82.7% | $3.17M+359% | ||
| -$33.58M+1.1% | -$29.73M+86.2% | -$45.74M+73.6% | -$27.18M+80.7% | -$33.96M+72.5% | ||
| —— | —— | —— | —— | —— | ||
| $756.13M+39.3% | $890.31M+9.9% | $462.98M-42.6% | $263.66M-66.6% | $542.75M+25.1% | ||
| $281.29M— | $458.35M— | —— | —— | —— | ||
| -$443.4M-37.3% | -$405.13M-37.4% | -$378.22M-54.7% | -$361.93M-64.3% | -$322.89M-46.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dyne Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.